Cancer, diabetes leave fingerprints in blood, serum

Tue Sep 2, 2008 8:22am EDT
 
[-] Text [+]

HONG KONG (Reuters) - Diseases such as cancer and diabetes leave "fingerprints" in the serum and blood plasma of patients and these may provide a valuable and non-invasive diagnostic tool in time to come, according to a Chinese study.

In an article published in the latest issue of Cell Research, the Chinese researchers described how they found such altered molecular biomarkers, called microRNAs, to be stable in the serum and blood of people who were ill.

"This is a revolutionary finding, this is the first time we have been able to demonstrate that microRNA is stable in serum," Zhang Chen-yu at the Jiangsu Diabetes Centre in China's eastern province of Jiangsu told Reuters by telephone.

The scientists analyzed the blood of both healthy people and patients with lung cancer, colorectal cancer and diabetes, and found that those who were ill had altered biomarkers that were vastly different from the healthy participants.

Zhang said patients of one disease would have biomarkers that were markedly different from patients of another disease -- and in theory, doctors can tell what disease is afflicting a person by just analyzing the blood.

"We found different (classes of) biomarkers for lung cancer, colorectal cancer and diabetes, these biomarkers can reflect almost all pathological conditions," Zhang said.

This means diagnosis can be made without current invasive methods, which include removing tissue samples.

Looking ahead, Zhang said the team hoped to push for such biomarker screenings to be done in local clinics to alleviate the pressure on overcrowded government hospitals.

(Reporting by Tan Ee Lyn; Editing by Bill Tarrant)

 
Dr. Qurrath U. Ain of the Elmhurst Pediatric Emergency Center examines a patient with flu-like symptoms at Elmhurst Hospital in New York in this December 12, 2003. file photo. REUTERS/Shannon Stapleton/Files
Healthcare Reform

Reuters provides an in-depth look at the issues facing Americans as the Obama administration wrestles with healthcare policy.  Full Coverage 

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
A pharmacist holds bottles of the prescription arthritis and pain medication VIOXX at a New York City Pharmacy after manufacturer Merc Research Laboratories announced a worldwide voluntary withdrawal of the drug September 30, 2004
Risky negotiations

While the government may be able to negotiate prescription cost-savings up front, the long term effect would hurt pharmaceutical innovation, writes Peter J. Pitts   Commentary | Full Coverage 

Join the Reuters Consumer Insight Panel and help us get to know you better

Join the Reuters Consumer Insight Panel and help us get to know you better